Auger Kyle, Lee Jason, Hong Ian S, Jankowski Jaclyn M, Liporace Frank A, Yoon Richard S
Division of Orthopaedic Trauma & Adult Reconstruction, Department of Orthopaedic Surgery, Cooperman Barnabas Medical Center-RWJBarnabas Health, Livingston, NJ 07039, USA.
Division of Orthopaedic Trauma & Adult Reconstruction, Department of Orthopaedic Surgery, Jersey City Medical Center-RWJBarnabas Health, Jersey City, NJ 07302, USA.
J Clin Med. 2024 May 9;13(10):2785. doi: 10.3390/jcm13102785.
The benefits of denosumab as an antiresorptive therapy and in reducing fragility fractures are well documented. However, its association with atypical femur fractures (AFFs), especially in the absence of prior bisphosphonate use, remains poorly understood and warrants further investigation. This case report presents a rare instance of bilateral AFFs in a 78-year-old bisphosphonate-naïve patient with a history of long-term denosumab therapy for previous metastatic breast cancer. Management involved intramedullary nail fixation after initial presentation with a unilateral AFF and a recommendation to cease denosumab therapy. However, the patient subsequently experienced a contralateral periprosthetic AFF below a total hip implant 5 months thereafter and was treated with open reduction internal fixation. This case report highlights the critical need for orthopedic surgeons to maintain a high level of suspicion and vigilance in screening for impending AFFs, especially in patients with a prolonged history of denosumab therapy without prior bisphosphonate use. Furthermore, the growing report of such cases emphasizes the urgent need for comprehensive research aimed at refining treatment protocols that balance the therapeutic benefits of denosumab and its associated risks of AFFs.
地诺单抗作为一种抗骨吸收疗法以及在降低脆性骨折方面的益处已有充分记录。然而,其与非典型股骨骨折(AFFs)的关联,尤其是在未使用过双膦酸盐类药物的情况下,仍了解甚少,值得进一步研究。本病例报告呈现了一名78岁未使用过双膦酸盐类药物的患者罕见的双侧AFFs情况,该患者因既往转移性乳腺癌接受了长期地诺单抗治疗。治疗包括在初次出现单侧AFF后进行髓内钉固定,并建议停止地诺单抗治疗。然而,患者随后在5个月后于全髋关节置换植入物下方出现对侧假体周围AFF,并接受了切开复位内固定治疗。本病例报告强调,骨科医生在筛查即将发生的AFFs时迫切需要保持高度怀疑和警惕,尤其是在有长期地诺单抗治疗史且未使用过双膦酸盐类药物治疗的患者中。此外,此类病例报告的不断增加凸显了迫切需要进行全面研究,以完善治疗方案,平衡地诺单抗的治疗益处及其相关的AFFs风险。